15-pgdh in colon cancer
AssigneesThe Brigham and Women's Hospital, Inc., Case Western Reserve University
InventorsSanford D. Markowitz, Monica Bertagnolli
Life of this patent
Estimating the term…
Abstract
The disclosure provides, among other things, a method of decreasing resistance to the chemopreventive properties of non-steroidal anti-inflammatory agents, e.g., celecoxib, particularly in the prevention of cancer, e.g., colon cancer, by increasing the levels or activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The disclosure also provides a method of identifying compounds that upregulate or reactivate 15-PGDH. The disclosure also provides a method of identifying an individual suitable for treatment with a non-steroidal anti-inflammatory agent in the treatment or prevention of colon cancer.
Claims19
1-23. (canceled)
A method of treating an NSAID-responsive condition comprising administering an effective amount of an NSAID and an agent that upregulates 15-PGDH, wherein the agent is not a Prox-1 suppressor.
The method according to claim 28, wherein the NSAID-responsive condition is selected from the group consisting of:
- pain disorders, inflammatory disorders, or immunologic disorders.
A method of decreasing NSAID resistance in a patient, comprising administering:
- (i) an effective amount of a compound that increases 15-PGDH levels or 15-PGDH activity;
- Or
- (ii) an effective amount of 15-PGDH protein, cDNA, or an active fragment thereof, wherein a compound that increases 15-PGDH levels is not a Prox-1 suppressor.
41-61. (canceled)
Dependencies are inferred from the claim text.